JP2024514995A5 - - Google Patents
Info
- Publication number
- JP2024514995A5 JP2024514995A5 JP2023544357A JP2023544357A JP2024514995A5 JP 2024514995 A5 JP2024514995 A5 JP 2024514995A5 JP 2023544357 A JP2023544357 A JP 2023544357A JP 2023544357 A JP2023544357 A JP 2023544357A JP 2024514995 A5 JP2024514995 A5 JP 2024514995A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- crystalline form
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218504P | 2021-07-06 | 2021-07-06 | |
| US63/218,504 | 2021-07-06 | ||
| PCT/US2022/036260 WO2023283269A1 (en) | 2021-07-06 | 2022-07-06 | Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514995A JP2024514995A (ja) | 2024-04-04 |
| JP2024514995A5 true JP2024514995A5 (enExample) | 2024-08-20 |
| JP7565118B2 JP7565118B2 (ja) | 2024-10-10 |
Family
ID=84802010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544357A Active JP7565118B2 (ja) | 2021-07-06 | 2022-07-06 | （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12240858B2 (enExample) |
| EP (1) | EP4330259A4 (enExample) |
| JP (1) | JP7565118B2 (enExample) |
| KR (1) | KR102783648B1 (enExample) |
| CN (1) | CN116916922B (enExample) |
| AU (1) | AU2022307875B2 (enExample) |
| BR (1) | BR112023024853A2 (enExample) |
| CA (1) | CA3217088A1 (enExample) |
| IL (1) | IL308946B2 (enExample) |
| MX (1) | MX2023013093A (enExample) |
| TW (1) | TWI809967B (enExample) |
| WO (1) | WO2023283269A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI906763B (zh) * | 2024-02-05 | 2025-12-01 | 財團法人國家衛生研究院 | 表皮生長因子受體抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507502B2 (en) * | 2008-11-10 | 2013-08-13 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| KR101301533B1 (ko) * | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
-
2022
- 2022-07-05 TW TW111125153A patent/TWI809967B/zh active
- 2022-07-06 JP JP2023544357A patent/JP7565118B2/ja active Active
- 2022-07-06 CA CA3217088A patent/CA3217088A1/en active Pending
- 2022-07-06 BR BR112023024853A patent/BR112023024853A2/pt unknown
- 2022-07-06 CN CN202280009812.5A patent/CN116916922B/zh active Active
- 2022-07-06 IL IL308946A patent/IL308946B2/en unknown
- 2022-07-06 WO PCT/US2022/036260 patent/WO2023283269A1/en not_active Ceased
- 2022-07-06 AU AU2022307875A patent/AU2022307875B2/en active Active
- 2022-07-06 KR KR1020237023847A patent/KR102783648B1/ko active Active
- 2022-07-06 MX MX2023013093A patent/MX2023013093A/es unknown
- 2022-07-06 US US17/858,321 patent/US12240858B2/en active Active
- 2022-07-06 EP EP22838355.0A patent/EP4330259A4/en active Pending
-
2024
- 2024-07-17 US US18/775,916 patent/US20240368175A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532790A5 (enExample) | ||
| JP2022058395A5 (enExample) | ||
| JP2023539715A5 (enExample) | ||
| TWI594986B (zh) | Antineoplastic agent effect enhancer | |
| CN107296811B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2023545096A5 (enExample) | ||
| JP2022520382A5 (enExample) | ||
| JP2023542093A5 (enExample) | ||
| JP2013505249A5 (enExample) | ||
| WO2011021597A1 (ja) | キノリン誘導体含有医薬組成物 | |
| JP2017512791A5 (enExample) | ||
| JP2014527042A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| AU2017205749B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2024514995A5 (enExample) | ||
| JP2023503167A5 (enExample) | ||
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP7045726B2 (ja) | Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤 | |
| WO2011050684A1 (zh) | 治疗肿瘤疾病的药物组合物 | |
| ES2385850T3 (es) | Potenciador de radioterapia | |
| IL308946B1 (en) | Crystalline form of (s,e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[3,2-d]pyrimidin-5-yl)phenyl)but-2-ynamide free base | |
| JP2023542065A5 (enExample) | ||
| CN102770026B (zh) | 组合 | |
| JP2024515061A5 (enExample) | ||
| JP2024524701A5 (enExample) |